The question here is simple: which parts of this product are genuinely hard, and which parts are mostly a very profitable coordination habit?
type 2 diabetes medicine
Once-weekly tirzepatide injection for improving blood glucose control in adults and children 10 and older with type 2 diabetes.
Mounjaro is a flagship cardiometabolic product for Lilly and a major contributor to the company's revenue growth, reinforcing its position in diabetes care while sharing the tirzepatide platform with obesity treatment under Zepbound.
Replacement sketch
Alternatives
These alternatives are not always drop-in replacements. They do, however, show where the incumbent's pricing power starts facing open pressure.
Disruptive concepts
These are not just existing alternatives. They are structured product ideas for how open coordination, Bitcoin rails, or decentralized production could attack the incumbent's capture points.
A publishable open or decentralized disruption concept would be misleading here because the product's real competitive constraints are patent protection, FDA-regulated evidence generation, and GMP manufacturing. Even lower-cost future substitutes would still be centralized pharmaceutical products rather than open or protocol-native replacements.
Technology waves
These are the repo's explicit bias terms: the technologies expected to keep making incumbents less inevitable over time.
Sources
Primary source for company business description, 2025 revenue, 2025 net income, product concentration, and tirzepatide revenue disclosures.
Used for Mounjaro indication, dosing form, and prescription-product framing.
Used for original approval context and mechanism description for Mounjaro.